Raise closed, search for fresh raises on Seedstage

Framingham, MA

Developing AI-driven biomarker tests to improve therapy outcomes and reduce healthcare costs.

• AI-Driven Biomarkers: Utilizing AI and mRNA biomarkers for precise treatment predictions.
• Strong Market Position: One of the few TNFi response tests in development with superior accuracy.
• Strategic Partnerships: Collaborating with Liquid Biosciences and SmartHealth Diagnostics for efficient market entry.
• Broad Market Potential: Targeting autoimmune diseases, behavioral health, and other high-cost conditions.
• Patent Protection: Products secured with patents through 2038, ensuring long-term market advantage.

Ignite Biomedical is dedicated to transforming precision medicine by developing AI-driven biomarker tests aimed at improving therapy outcomes in autoimmune diseases and behavioral health. The company’s leading product, the Tumor Necrosis Factor Inhibitor (TNFi) treatment response predictor, uses mRNA biomarkers from blood samples to predict a patient’s likelihood of responding to TNFi therapy within 24-48 hours. This innovative approach seeks to optimize patient care by matching individuals with the right treatment, reducing unnecessary healthcare costs, and improving clinical outcomes. The TNFi market alone presents a significant opportunity, with over $30 billion in U.S. sales and a high rate of non-response to current treatments. Ignite Biomedical’s early studies suggest their test could significantly outperform existing options, providing nearly 100% accuracy in detecting both responders and non-responders.

The funds raised will support the continued development and validation of the TNFi predictor and help expand Ignite Biomedical’s biomarker portfolio into other high-value markets, such as inflammatory bowel disease (IBD) and substance use disorders. The company plans to publish its findings in peer-reviewed journals and aims to launch its TNFi biomarker commercially by early 2027. With patent protection secured through 2038, Ignite Biomedical is strategically positioned to lead in the precision medicine space, offering clinicians the tools to make data-driven decisions that enhance patient outcomes while reducing wasteful healthcare spending. The company has already raised $1.5 million in a pre-seed round and is seeking additional funding to advance its pipeline of diagnostic and prognostic biomarker tests.

Company Info

Ignite Biomedical develops AI-driven biomarkers to improve treatment response prediction and precision medicine for autoimmune diseases and behavioral health.

Ignite Biomedical is developing AI-driven biomarkers aimed at enhancing precision medicine, particularly in autoimmune disease and behavioral health. The company’s flagship product, a Tumor Necrosis Factor Inhibitor (TNFi) treatment response predictor test, aims to address the inefficiency and waste in the current healthcare system by identifying patients who will respond or not respond to specific therapies. This blood-based test uses mRNA biomarkers to provide results in 24-48 hours, improving patient care and reducing unnecessary healthcare costs. Ignite’s TNFi test is positioned within a market opportunity worth over $1.2 billion.

The company has formed key partnerships, including one with Liquid Biosciences and SmartHealth Diagnostics, to expedite product development and bring its innovations to market. The TNFi treatment response test has demonstrated near-100% accuracy in early studies, and the company plans to expand its portfolio with additional biomarker tests. Ignite Biomedical’s products are patent-protected until 2038, positioning it well for long-term success in the precision medicine market. The company is also exploring other opportunities, including tests for behavioral health conditions, substance use, and inflammatory bowel disease (IBD), which offer significant market potential.